Cargando…
A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein. Approximately 30% of severe hemophilia A pati...
Autores principales: | Chen, Alex C., Cai, Xiaohe, Li, Chong, Khoryati, Liliane, Gavin, Marc A., Miao, Carol H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198749/ https://www.ncbi.nlm.nih.gov/pubmed/32411127 http://dx.doi.org/10.3389/fimmu.2020.00638 |
Ejemplares similares
-
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020) -
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017) -
Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016) -
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023) -
Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)